Odyssey Therapeutics Announces $218 Million Series A Financing To Advance Next Generation Inflammation And Oncology Medicines
Odyssey Therapeutics Announces $218 Million Series A Financing To Advance Next Generation Inflammation And Oncology Medicines
12/07/21, 7:00 AM
Location
bostonMoney raised
$218 million
Round Type
series a
Odyssey Therapeutics, a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today announced the completion of an oversubscribed $218 million Series A financing led by OrbiMed Advisors and co-led by SR One Capital Management with participation from Foresite Capital, Woodline Partners LP, Logos Capital, HBM Healthcare Investments, Colt Ventures, Creacion Ventures, and other institutional investors. Carl L. Gordon, Ph.D., Managing Partner of OrbiMed Advisors, will join Odyssey's board of directors. The financing will be used to advance multiple pipeline programs and Odyssey's discovery platform aimed at expanding the druggable genome
Company Info
Location
boston, massachusetts, united states
Additional Info
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next generation immunomodulators and oncology medicines. Comprised of an expert team of drug hunters and executives, Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. For more information, please visit www.odysseytx.com.